Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787722 · ClinicalTrials.gov registry record · Phase 1
Hematopoietic Stem Cell Transplant in Devic's Disease
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00787722 is a Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 13 participants.
The verdict
NCT00787722, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study is designed to examine whether treating Devic's disease patients with high dose cyclophosphamide together with rabbit antithymocyte globulin (rATG)/rituximab (drugs which reduce the function of the immune system), followed by return of previously collected patient's stem cells will result in improvement in Devic's disease. Stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood stream. The purpose of the intense chemotherapy is to destroy the cells in patient's immune system, which may be causing his/her disease. The purpose of the stem cell infusion is to produce a normal immune system that will no longer attack patient's body. The purpose of study is to examine the safety and efficacy of this treatment. The drugs used in this study treatment are drugs for commonly used for immune suppression.
Interventions
- DRUG Cyclophosphamide
- DRUG Mesna
- DRUG G-CSF
- PROCEDURE Hematopoietic Stem Cell Transplantation
- DRUG rATG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-10-10 |
| Est. Completion | 2018-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00787722
The ClinicalTrials.gov registry entry for NCT00787722 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00787722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00787722 about?
NCT00787722 is a clinical study titled "Hematopoietic Stem Cell Transplant in Devic's Disease". This study is designed to examine whether treating Devic's disease patients with high dose cyclophosphamide together with rabbit antithymocyte globulin (rATG)/rituximab (drugs which reduce the function of the immune system), followed by return of previously collected patient's stem cells will result...
What is the current status of trial NCT00787722?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2009-10-10. Estimated completion is 2018-11.
What interventions are being tested in trial NCT00787722?
The interventions under investigation include: Cyclophosphamide (DRUG), Mesna (DRUG), G-CSF (DRUG), Hematopoietic Stem Cell Transplantation (PROCEDURE), rATG (DRUG).
Who is sponsoring clinical trial NCT00787722?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.